CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy

Contributed by: PR Newswire

Images

PR Newswire associated0
PR Newswire associated1

Tags

CSLVifor-TravereThera

More Like This

PR Newswire associated0

CSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA Nephropathy

PR Newswire associated0

Veltassa® (patiromer) approved in Japan for the treatment of adults with hyperkalemia

Calliditas partner STADA receives European Commission decision for full approval of Kinpeygo® for the treatment of IgA Nephropathy

STADA and Calliditas announce the filing for full marketing authorization of Kinpeygo® in the EU

Calliditas partner STADA receives positive CHMP opinion recommending full approval for Kinpeygo® for the treatment of IgA nephropathy

Calliditas Therapeutics announces full FDA approval of TARPEYO®, the only FDA-approved treatment for IgA nephropathy to significantly reduce the loss of kidney function

Hansa Biopharma completes enrolment in European Phase 3 20-HMedIdeS-19 Post Authorization Efficacy and Safety study in highly sensitized kidney transplant patients

EMA validates indication extension application for Aspaveli® for treatment of C3G and primary IC-MPGN